Rising Japan diabetes competition tugs at Novo Nordisk
This article was originally published in Scrip
Executive Summary
Intensifying competition in Japan's diabetes market, including the rapid rise of new small molecule drugs, is creating a more challenging operating environment for local insulin market leader Novo Nordisk.